News

This summer, high school students from Appalachian Kentucky spent five weeks at UK gathering real-life experience in oncology training and research as part of the UK Markey Cancer Center's successful ACTION Program.

A new study by Markey researchers shows a higher mortality rate for prostate cancer among men from Appalachian Kentucky compared to men from non-Appalachian Kentucky.

Aime Kunes decided to participate in a health research study because she wanted to learn more about the process of research. With a Ph.D. in psychology and a background in neurofeedback, she was planning to conduct her own research and felt it was important to understand the experience of a participant.

A new public health initiative supported by $11 million in funding from the National Cancer Institute aims to address the burden of cervical cancer incidence and mortality in Appalachia.

Could people in Eastern Kentucky, whose primary water sources have high levels of arsenic, take zinc to prevent cancer? Cancer epigeneticist Yvonne Fondufe-Mittendorf says her data points to this non-invasive fix.

The University of Kentucky Markey Cancer Center and Leukemia and Lymphoma Society (LLS) recently hosted their eighth annual “Meet the Researchers” Day. This event is a field trip given as a prize to two schools in the region who successfully raised more than $1,000 for the LLS’s Pennies for Patients campaign.

Jennifer Havens has spent the past decade studying the transmission of infectious disease and advocating for the expansion of harm reduction programs. That work entails understanding the link between two health burdens facing the nation, the opioid crisis and cancer.

The University of Kentucky Markey Cancer Center celebrated 10 years of Markey Research Day this past Tuesday, May 7, 2019, with nearly 450 attendees, 138 poster presentations and oral presentations.

After reviewing more than 90 applications for the program, a Markey committee has selected 20 high school students to enroll in the ACTION program for the 2019 class.

The team led by Glazer and Heidary is currently focusing on structure-based drug design to try to target a specific enzyme that is involved in cancer initiation, malignant progression and, most important, resistance to chemotherapy. And they have had some recent success.